Skip to main content

Table 3 Prevalence of ESBL- Ec sensitive to additional antibiotics for each country visited a

From: High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coliin Swiss Travellers to South Asia– a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors

 

All countries (n = 157)

India (n = 82)

Bhutan (n = 15)

Nepal (n = 41)

Sri Lanka (n = 19)

AMC

58.6

59.8

73.3

56.1

47.4

PIP-TAZ

96.8

95.1

100.0

95.1

100.0

CEP

35.0

46.3

26.7

24.4

15.8

MEM

100.0

100.0

100.0

100.0

100.0

SXT

51.0

48.8

73.3

51.2

42.1

CIP

59.2

47.6

86.7

70.7

63.2

NF

98.1

98.8

93.3

97.6

100.0

FOS

99.4

100.0

100.0

97.6

100.0

AMK

95.5

96.3

100.0

95.1

89.5

TOB

82.2

76.8

100.0

87.8

79.0

COL

100.0

100.0

100.0

100.0

100.0

  1. Note: AMC, amoxicillin-clavulanate; PIP-TAZ, piperacillin-tazobactam; CEP, cefepime; MEM, meropenem; SXT, thrimetoprim-sulfamethoxazole; CIP, ciprofloxacin; NF, nitrofurantoin; FOS, fosfomycin; AMK, amikacin; TOB, tobramycin; COL, colistin.
  2. astated as %.